Best therapists: TOP 169 doctors

Experience

2021 year - 2022 year

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2021 year - 2022 year

Department of Radiation Oncology, Biruni University Faculty of Medicine

2020 year - 2021 year

Clinical Manager of Radiation Oncology, Medicana International Istanbul Hospital

2017 year - 2020 year

Clinical Manager of Radiation Oncology, Neolife Medical Center

2016 year - 2017 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2011 year - 2016 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2010 year - 2011 year

Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine

2008 year - 2010 year

Radiation Oncology Clinic, Samsun Training and Research Hospital (Education Coordinator)

2006 year

Medical Faculty, Dokuz Eylül University

2006 year - 2008 year

Radiation Oncology Clinic, Samsun Mehmet Aydın State Hospital (Compulsory Service)

2000 year - 2006 year

Medical Faculty, Dokuz Eylül University

Education

2022 year

Biruni University Faculty of Medicine, Department of Radiation Oncology, Faculty Member, Professor Doctor

2022 year

Anadolu University Open Education Faculty Undergraduate Program, Cultural Heritage and Tourism

2021 year

Feyziye Schools Foundation Işık University Health Services Vocational School, Faculty Member, Associate Professor Doctor

2017 year

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Faculty Member

2017 year

Eskişehir Osmangazi University Faculty of Medicine, Department of Radiation Oncology, Associate Professor Doctor

2006 year

Samsun Training and Research Hospital, Specialist Doctor, Compulsory Service

2006 year

Dokuz Eylül University Faculty of Medicine, Department of Radiation Oncology, Medical Specialization

1998 year

Ege University, Faculty of Medicine

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Dr. Pongsapisut Poonsawatphong, widely known as “Doctor Ek,” is a prominent psychiatrist in Thailand who has made significant contributions to the field of mental health. With years of professional experience, he is recognized for his clinical expertise and his leadership in shaping mental health services that are both accessible and stigma-free. He currently serves as an executive of the SMIND network and is also the resident psychiatrist at the SMIND Mental Health Clinic located in Khon Kaen.

Dr. Pongsapisut’s career includes prior service at Srinagarind Hospital, a leading teaching hospital affiliated with Khon Kaen University, where he was actively involved in psychiatric care, education, and community outreach. His approach emphasizes not only treatment but also mental health promotion and preventive care. This philosophy is evident in the services provided at SMIND, which operates under the concept “You don’t have to be sick to come,” encouraging people to seek mental wellness proactively.

In addition to his medical career, Dr. Pongsapisut is also known for his advocacy on social issues. In October 2020, he was among the group of medical professionals who signed a public statement calling for an end to violence against peaceful protesters in Thailand. This action demonstrated his dedication to human rights, ethical responsibility, and social justice—principles that deeply influence his approach to psychiatry.

Dr. Pongsapisut continues to be a leading voice in mental health reform, striving to break down social stigmas and promote psychological well-being across all sectors of Thai society.

Dr. Akif Nuri Doğan is an internal medicine specialist. He graduated from Cerrahpaşa School of Medicine, Istanbul University in 2002. He completed his residency at Bezm-i Alem Vakıf Gureba Teaching and Research Hospital in 2008.

He works at Hisar Hospital Intercontinental. He provides assessment, diagnosis, and treatment for internal diseases. His main areas of focus are obesity, reflux, hypertension, diabetes, and chronic fatigue.

Dr. Doğan has gained experience at Elazig Military Hospital, Antalya Training and Research Hospital, and Akseki State Hospital. He is known for his evidence-based approach and dedication to patient care.

Prof. Dr. Levent Kılıçkan graduated from Trakya University Faculty of Medicine in 1989. He completed his residency at Istanbul Taksim Hospital in 1994. He became an associate professor at Kocaeli University Medical Hospital in 2001. In 2006, he was promoted to full professor at Kocaeli University Faculty of Medicine.

Dr. Kılıçkan has attended many national and international medical events. His main areas of interest are intensive care, regional anesthesia, organ transplantation, and cardiovascular anesthesia.

• Specializes in Therapy for autoimmune and chronic degenerative diseases.
• International training in Mexico, Spain, and France.
• Expert in mesenchymal stem cell protocols for Therapy treatment.
• Holds a Master’s Degree in Regenerative Medicine.
• Member of HemoFenix France and Kimicor Pharma in Mexico.
• Offers online consultations for Therapy-related health concerns.

Education and Expertise

1993-1999 Istanbul University Istanbul Faculty of Medicine

2000-2005 Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, specialization training

Experience

2020 - …: Beykent University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2015 - 2020: Bahçeşehir University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2008 -2021: Medical Park Fatih Hospital Physical Medicine and Rehabilitation Clinic

2007 - 2008: Elazig Military Hospital Physical Therapy Clinic

2005 - 2007: Bayrampaşa Physical Therapy and Rehabilitation Center for the Disabled

2000 - 2005: Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

Professional Memberships

1. Turkish Medical Association

2. Turkish Physical Medicine and Rehabilitation Association

3. Member of Istanbul Medical Chamber,

4.Pediatric Rehabilitation Association

Awards

1 - National Thoracic Oncology Congress, p38, Antalya, 2008 (BEST POSTER AWARD). Demir A, M. Z. Gunluoğlu, N. Dağoğlu, A.Turna, Y. Dizdar, K. Kaynak, Ş. Dilege, N.M. Molinas, D. Yilmazbayhan, S.İ.Dinçer, A.Gürses “The role and prognosis of surgery in the treatment of chest wall primitive neuroectodermal tumors”.

2 - National Thoracic Oncology Congress, 109, Marmaris, 2007 (BEST ORAL PRESENTATION AWARD) Melek, H., M. Günlüoğlu, A. Demir, B. Medetoğlu, H.V. Kara, A. Ölçmen, S.İ. Dinçer, "The superiority of Computed Tomography-integrated PET (PET-CT) over PET fusion CT in Mediastinal Staging of Lung Cancer".

3 - Thoracic Society 9th Annual Congress, 92, Antalya, 2006. (BEST DISCUSSIVE POSTER AWARD) Fazlıoğlu, M., C. Kocatürk, Y. Sönmezoğlu, A.G. Cevik, A. Demir, N. Ürer, A.Turna, S.İ. Dincer M.A. Bedirhan and A. Gürses, “The effect of NSCLC with chest wall invasion DA depth of invasion and resection type on survival”.

4 - National Thoracic Oncology Congress, TP , Çeşme, 2006. (BEST DISCUSSIVE POSTER AWARD).Günlüoğlu, M.Z., A. Demir, H. Akın, D. Sansar, H.V. Kara, A. Ölçmen and S.İ. Dinçer, “Mediastinal lymphatic metastasis pattern in left upper lobe non-small cell lung cancer”. Education and Specialization

1993-1999 Istanbul University Istanbul Faculty of Medicine

2000-2005 Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, specialization training

Experience

2020 - …: Beykent University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2015 - 2020: Bahçeşehir University Faculty of Medicine Department of Physical Medicine and Rehabilitation

2008 -2021: Medical Park Fatih Hospital Physical Medicine and Rehabilitation Clinic

2007 - 2008: Elazig Military Hospital Physical Therapy Clinic

2005 - 2007: Bayrampaşa Physical Therapy and Rehabilitation Center for the Disabled

2000 - 2005: Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

Professional Memberships

1. Turkish Medical Association

2. Turkish Physical Medicine and Rehabilitation Association

3. Member of Istanbul Medical Chamber,

4.Pediatric Rehabilitation Association

Awards

1 - National Thoracic Oncology Congress, p38, Antalya, 2008 (BEST POSTER AWARD). Demir A, M. Z. Gunluoğlu, N. Dağoğlu, A.Turna, Y. Dizdar, K. Kaynak, Ş. Dilege, N.M. Molinas, D. Yilmazbayhan, S.İ.Dinçer, A.Gürses “The role and prognosis of surgery in the treatment of chest wall primitive neuroectodermal tumors”.

2 - National Thoracic Oncology Congress, 109, Marmaris, 2007 (BEST ORAL PRESENTATION AWARD) Melek, H., M. Günlüoğlu, A. Demir, B. Medetoğlu, H.V. Kara, A. Ölçmen, S.İ. Dinçer, "The superiority of Computed Tomography-integrated PET (PET-CT) over PET fusion CT in Mediastinal Staging of Lung Cancer".

3 - Thoracic Society 9th Annual Congress, 92, Antalya, 2006. (BEST DISCUSSIVE POSTER AWARD) Fazlıoğlu, M., C. Kocatürk, Y. Sönmezoğlu, A.G. Cevik, A. Demir, N. Ürer, A.Turna, S.İ. Dincer M.A. Bedirhan and A. Gürses, “The effect of NSCLC with chest wall invasion DA depth of invasion and resection type on survival”.

4 - National Thoracic Oncology Congress, TP , Çeşme, 2006. (BEST DISCUSSIVE POSTER AWARD).Günlüoğlu, M.Z., A. Demir, H. Akın, D. Sansar, H.V. Kara, A. Ölçmen and S.İ. Dinçer, “Mediastinal lymphatic metastasis pattern in left upper lobe non-small cell lung cancer”.

EXPERIENCE*

2019 - Present, Istanbul/Istanbul/Turkey

MEMORIAL ATAŞEHİR HOSPITAL

General Surgeon

2012 - 2019, Diyarbakır/Diyarbakır/Turkey

DİCLE UNIVERSITY FACULTY OF MEDICINE

General Surgeon

2011 - 2012, Van/Van/Turkey

VAN REGIONAL TRAINING AND RESEARCH HOSPITAL

General Surgeon

2009 - 2011, Van/Van/Turkey

HAKKARİ STATE HOSPITAL

General Surgeon

2004 - 2009, Van/Van/Turkey

YÜZÜNCÜYIL UNIVERSITY FACULTY OF MEDICINE

General Surgeon

2002 - 2004, Van/Van/Turkey

HACIBEKİR HEALTH CENTER

General Practitioner

*EDUCATION*

2018 - 2019, Diyarbakır/Turkey

Associate Professor

2015, Ohio/USA

OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Neck Dissection Training

2012 - 2018, Diyarbakır/Turkey

Assistant Professor

1996 - 2002, Adana/Turkey

ÇUKUROVA UNIVERSITY

FACULTY OF MEDICINE - Medical Doctor Education

Areas of activity: • Research of pathology in gerontological age group (elderly) patients • Clinical nutrition (enteral and parenteral nutrition) • Diabetes mellitus, metabolic syndrome, osteoporosis, thyroid diseases • Arterial hypertension • High body temperature of unknown genesis (fever) • Diseases of the musculoskeletal system, rheumatological diseases • Diseases of the gastrointestinal tract, liver • Disorders of water and electrolyte metabolism, kidney diseases Education: • Higher education - Azerbaijan Medical University, Faculty of General Medicine and Prevention, 2008-2014 • Specialization – Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine Work experience: • Baku State Hospital No. 3, resident physician nephrologist. 2014-2016 • Istanbul Private Bahcelievler Memorial Hospital, specialist in internal medicine. 2021-2022 Research work: (dissertation / defense) • Clinical and laboratory features of patients with acute interstitial nephritis diagnosed during kidney biopsy, factors influencing the etiology and response to treatment. Istanbul University, Istanbul Faculty of Medicine, Department of Nephrology, 2021 Publications:(2) •P343Efficacy of adalimumab mild-to-moderate inflammatory bowel disease: Real-life data from a single-centre experience in the long-term period. January 2020 Journal of Crohns and Colitis DOI: 10.1093/ecco-jcc/jjz203.472 •Concurrent myelomatous pleural effusion and extramedullary mediastinalinvolvement as a relapse manifestation of multiple myeloma. Abstract of the IXth International Eurasian Hematology OncologyCongress17–20October2018Istanbul,Turkey(Concomitant myelomatous pleurisy and extramedullary mediastinal lesion as a recurrent manifestation of multiple myeloma. Abstracts of the IX International Eurasian Oncohematology Congress17–20October2018Istanbul,Türkiye) Memberships in scientific organizations: •Turkish Medical Association

Dr. Victor Alexander Krol - Chief of Gastroenterology, Internal Medicine and Obesity Treatment Center at Martinus Hospital

Dr. Victor Alexander Krol is a highly qualified specialist, heading the departments of gastroenterology and internal medicine. With many years of experience and deep knowledge in his field, Dr. Krol has established himself as an outstanding expert, providing patients with comprehensive treatment and an individual approach. He actively uses the latest methods of diagnosis and treatment of diseases of the gastrointestinal tract, metabolism, as well as diseases of the cardiovascular and respiratory systems.

Dr. Krol is also the director of the certified Obesity Treatment Center at Martinus Hospital, which provides surgical and endoscopic treatments for obesity. The center uses advanced technology to diagnose and treat obesity (adiposis), including methods such as bariatric surgery, endoscopic weight loss, and specialized programs for patients with different stages of obesity. The center is certified to high standards and has excellent results in the treatment of this serious disease.

The Gastroenterology Department, headed by Dr. Krol, diagnoses and treats diseases of the stomach, intestines, liver, pancreas, and gallbladder. The doctors of the department use a wide range of methods, including endoscopic procedures, ultrasound, and other modern diagnostic technologies.

The Department of Internal Medicine covers a wide range of diseases, including cardiology, diabetology, infectology, and therapy of respiratory and renal diseases. Dr. Krol and his team provide a comprehensive approach to treatment using the most advanced methods of medicine.

Thanks to his high professionalism and humane approach to each patient, Dr. Krol deservedly enjoys the respect of colleagues and patients.

• Dr. Luis Padilla specializes in regenerative therapy for degenerative diseases.

Dr. Sutawadee Sukcharoensin brings over 15 years of expertise in orthopedic and regenerative medicine, specializing in anti-aging and all kind of stem cell therapy. With a profound dedication to advancing patient health, she integrates her extensive knowledge in cutting-edge regenerative treatments to provide tailored solutions that promote healing and rejuvenation. Dr. Sutawadee ’s commitment to excellence in anti-aging medicine and her skill in stem cell applications make her a sought-after expert in her field, ensuring the highest standards of care and innovation for her patients. She is an expert skills and certifications in regenerative medicine doctor.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education and Expertise

Medical Education: Istanbul University, Cerrahpaşa Faculty of Medicine (1995)

Specialization: Anesthesia and Reanimation, S.B. Haydarpaşa Numune Training and Research Hospital (2000 to 2005)

Master's Degree: İstinye University, Institute of Social Sciences, Health Management (2020 to 2022)

PhD: İstinye University, Faculty of Graduate Education, Health Management (2022 to Present)

Experience

1997 to 1999 – General Practitioner, Private Marmara Hospital (Maltepe University), Cardiology Department

2005 to Present – Anesthesiology and Reanimation Clinic, S.B. Haydarpaşa Numune Training and Research Hospital

2005 to 2006 – Responsible Physician of Anesthesia and Intensive Care, Grup Universal Hospital, Kadıköy

2006 to 2012 – General Intensive Care Responsible Physician, Group Florence Nightingale Hospitals, Şişli

2012 to 2017 – General Intensive Care Responsible Physician, Grup Memorial Service Hospital

2017 to 2018 – General Intensive Care Unit, VM Medical Park Hospital, Kocaeli

2018 to Present – Responsible Manager, General Intensive Care Unit, VM Medical Park Hospital, Pendik

Professional Memberships

-Turkish Medical Association

-Turkish Anesthesiology and Reanimation Association

-Turkish Intensive Care Association

-Turkish Neurology Association

-Skull Base Association

Professor Markus Dukes is a specialist in diagnostic radiology and minimally invasive therapy.

Awards

• Gold Medal of Honorary Professor of Osaka Medical University (Japan).
• Honorary member of DeGIR (German Society for Interventional Radiology and Minimally Invasive Therapy).

Education and professional experience

• 1982-1988 - study of human medicine at the Johannes-Gutenberg University in Mainz.
• 1988 - approval and medical license.
• 1988-1989 - Medical officer of the Bundeswehr.
• 1990 - Candidate of Medical Sciences in the field of radiology, subject: “Investigation of the influence of dilation speed on its success, as well as on damage to the vessel walls during balloon expansion”, at the Johannes-Gutenberg University in Mainz.
• 1990-1996 - Resident in the Department of Radiology at the Ruprecht-Karls University.
• 1996 - Senior physician in the Department of Radiodiagnostics at the Ruprecht-Karls University of Heidelberg.
• 1998 - Doctorate in Diagnostic Radiology, topic: "Direct comparison of imaging methods for gastric carcinoma: the importance of optimized examination methods in clinical practice and first experience with magnetic resonance imaging."
• 2000 - Deputy Head of the Department of Radiology, Department of Radiodiagnostics at the Ruprecht-Karls University of Heidelberg.
• 2000-2002 - Head of the Image Processing Center at the Orthopedic Clinic of the University of Heidelberg.
• 2002-2003 - Head of the Department of Radiology, Surgical Clinic, Department of Radiology at the Ruprecht-Karls University of Heidelberg.
• 2003 - Chief Physician of the Central Institute of Radiology and Neuroradiology at the Nordwest Clinic in Frankfurt am Main.
• 2006 - Associate Professor in the Department of Radiology at the University of Heidelberg.

Scientific activity

Marcus Dukes is one of the first physicians to perform minimally invasive microwave ablation of liver and lung tumors under CT guidance.

Clinical activities

The professor heads the first and only MRI-guided FUS ablation center in the Rhine-Main region. In most cases, the procedure allows avoiding surgical intervention. Patients of the center have access to ablation for prostate cancer, bone and liver metastases, benign tumors, and treatment of uterine fibroids without surgery.

Membership in organizations

• DRG (German Society of Radiologists).
• DeGIR (German Society for Interventional Radiology and Minimally Invasive Therapy).
• RSNA (Radiological Society of North America).
• ESGAR (European Society of Gastrointestinal and Abdominal Radiology).
• CIRSE (Cardiovascular and Interventional Radiology Society of Europe).
• ECR (European Congress of Radiology).
• EUFUS (European FUS Society).
• MEDICA (German Society for Interdisciplinary Medicine).

Through rigorous training and practical experience, they have developed a deep understanding of Urology, earning recognition for their diagnostic skills and effective treatment approaches. Dr. Ahmet Tevfik Albayrak is a distinguished member of the European Society for Sexual Medicine (ESSM), a testament to their expertise and dedication in the field of sexual health. As a member of the ESSM, Dr. Ahmet Tevfik Albayrak remains connected to a network of professionals dedicated to advancing the field of sexual medicine. Their contributions to research, education, and clinical practice have earned them recognition from their peers and gratitude from the patients they serve. Furthermore, through their involvement with the ESSM, Dr. Ahmet Tevfik Albayrak stays abreast of the latest developments in sexual medicine, ensuring that they are equipped with the knowledge and skills needed to provide the highest quality of care to their patients. Their commitment to excellence and their compassionate approach to patient care continue to make a meaningful impact on the field of sexual health.

Dr. Séverine Iborra is the Chief Physician of the Department of Gynecology and Obstetrics at Städtisches Klinikum Solingen. Her responsibilities include obstetrics, the delivery room, the neonatal unit, and gynecology. The department also includes the Senology/Breast Clinic at the Bergisches Breast Center Solingen, led by Dr. Manuela Seifert.

Dr. Séverine Iborra is originally from France. She began her medical studies at the University of Lyon and later transferred to Albert-Ludwigs University in Freiburg, where she received her medical license in 2007. She earned her doctorate in 2008 for experimental research in molecular oncology. From August 2008 to November 2013, Dr. Iborra worked as a resident at the University Women’s Clinic in Freiburg. After passing her specialist exams in gynecology and obstetrics, she continued her career as a specialist at the same clinic. In November 2015, she moved to RWTH University Hospital Aachen as a senior physician.

At the Clinic for Gynecology and Obstetrics, under the leadership of Prof. Dr. E. Stickeler, Dr. Iborra led the obstetrics department from 2017 to 2019. Since December 2017, she was responsible for organizing education in the department, and in October 2019, she became the Managing Senior Physician and Personnel Senior Physician of the clinic, a position she held until she moved to Solingen.

In addition to her scientific work, with numerous publications and presentations at major gynecological conferences, Dr. Iborra deepened her medical specialties. She obtained certifications in oncological diagnostics and therapy from the Gynecological Oncology Working Group, as well as additional qualifications in Cervical Pathology and Colposcopy (AGCPC), Urogynecology and Pelvic Reconstructive Surgery (AGUP), and the Professional Association of Gynecologists (BVF).

In 2019, Dr. Iborra successfully completed further specialization in “Gynecological Oncology” and “Special Obstetrics and Perinatal Medicine.” She is an active member of leading German medical societies in her field, including the German Society for Gynecology and Obstetrics, the Cervical Pathology and Colposcopy Working Group, and the German Society for Prenatal and Birth Medicine.

Treatments Offered in Our Gynecology Department

• Hysteroscopy and Dilation and Curettage (D&C) for diagnostic and therapeutic purposes.
• Removal of abnormal or symptomatic ovarian findings, such as cysts, while preserving the remaining ovary.
• Oophorectomy (removal of ovaries) in cases of abnormalities or preventively when indicated.
• Myomectomy (removal of uterine fibroids) while preserving the uterus.
• Conservative treatment of fibroids: either medication or embolization performed by radiology specialists.
• Hysterectomy with or without removal of the cervix.
• Diagnosis and clarification of unclear findings in the cervix, vagina, and vulva.
• Dysplasia treatment.
• Endometriosis management.
• Cancer treatment for vulvar, vaginal, cervical, uterine, and ovarian cancers.
• Treatment for incontinence and/or pelvic organ prolapse.

Whenever possible, we offer all procedures as minimally invasive treatments using laparoscopy or the Da Vinci robotic system.